By: Nick Paul Taylor
The FDA labeled BD's safety notice as a Class I event. The warning comes amid several actions from the agency on the safety of syringes.
Nick Paul Taylor is a freelance pharmaceutical and biotech writer, with a focus on providing insightful and informative articles in the healthcare industry. His work has been featured in various publications, including Fierce Pharma, LabPulse, Biotech, Med Tech News, Healthcare Dive, The Science Advisory Board, BioPharma Dive, Regulatory Affairs Professionals Society (RAPS), BioSpace, and Global Supply Chain News. Nick's articles cover a wide range of topics, including drug development, regulatory affairs, industry trends, and scientific advancements.
This information evolves through machine learning and human feedback. Improve this profile .